HaploX CUBE-ctDNA sequencing technology can accurately identify trace quantities of circulating tumor DNA in the blood, with sensitivity as low as 0.05%!
HaploX has the world's most advanced platforms: Illumina's NextSeq, HiSeq X Ten, NovaSeq 6000 serial sequencing and digital PCR, with sequencing throughput capability ranking second in the world, and tumor gene data output ranking first in China.
HaploX was formed by a group of young, talented scientists specializing in genomics, bioinformatics, molecular biology, medicine, machine learning, big data mining and other related areas.
May 2019, HaploX Laboratory was accredited by the College of American Pathologists' Laboratory Accreditation Program！<read more>
February 2019, HaploX Laboratory was given ten out of ten for CAP competence verification once again.<read more>
December 2018, HapLab passed the external quality test project Oncogene Panel Test conducted for EMQN excellently.<read more>
June 28, 2018, HaploX announced the completion of several hundred million B round financing. the industry leader—Shenzhen Capital Group Co., Ltd. assisted HaploX in researching cancer precision medicine.<read more>
HaploX CTO Shifu Chen revealed that sample store time might affect the result of TMB test.<read more>
HaploX combined Shenzhen People's Hospital team to explore early detection of colorectal cancer.<read more>